---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-020871"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T03:59:56.183835+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kintara reports Q3 FY2023 net loss of $3.3M; cash at $3.0M; GBM data expected by year-end

## Summary
- Net loss $3.3M ($1.94 per share) vs. $5.4M ($5.45) in prior-year quarter; R&D spending down 42%.
- Cash and cash equivalents $3.0M as of March 31, 2023; working capital $3.2M.
- Top-line data from registrational GBM AGILE study for VAL-083 expected before end of calendar 2023.
- Case study data from expanded access program for VAL-083 presented at AACR; REM-001 program paused to conserve cash.

## SEC filing metadata
- accession: 0000950170-23-020871
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000095017023020871/0000950170-23-020871-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000095017023020871/ktra-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-020871
- JSON: https://secwatch.observer/filing/0000950170-23-020871.json
- Plain text: https://secwatch.observer/filing/0000950170-23-020871.txt

## Key facts
- Earnings Releases
  TuHURA Biosciences, Inc./NV reported fiscal third quarter ended March 31, 2023 results: net income net loss of approximately $3.3 million, EPS $1.94 per share.
  - Period: fiscal third quarter ended March 31, 2023
  - Net income: net loss of approximately $3.3 million
  - EPS: $1.94 per share
  - Result: reported results
  source text: For the three months ended March 31, 2023, Kintara reported a net loss of approximately $3.3 million, or $1.94 per share, compared to a net loss of approximately $5.4 million, or $5.45 per share, for the three months ended March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1498382/000095017023020871/0000950170-23-020871-index.htm
- Earnings Releases
  TuHURA Biosciences, Inc./NV reported the nine months ended March 31, 2023 results: net income net loss of approximately $11.3 million, EPS $7.32 per share.
  - Period: the nine months ended March 31, 2023
  - Net income: net loss of approximately $11.3 million
  - EPS: $7.32 per share
  - Result: reported results
  source text: For the nine months ended March 31, 2023, Kintara reported a net loss of approximately $11.3 million, or $7.32 per share, compared to a net loss of approximately $17.2 million, or $22.39 per share, for the nine months ended March 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1498382/000095017023020871/0000950170-23-020871-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.